Target intelligence / Profile preview

Optic atrophy 1 mitochondrial dynamin-like GTPase (OPA1) (OPA1)

Target
OPA1
Molecular classification
Enzyme, GTPase, Dynamin-like GTPase
01

Overview

Optic atrophy 1 mitochondrial dynamin-like GTPase (OPA1) is a nuclear-encoded protein localized to the inner mitochondrial membrane, where it plays a critical role in mitochondrial dynamics (UniProt P58281). It is primarily responsible for mediating the fusion of the inner mitochondrial membrane and maintaining the structural integrity of mitochondrial cristae (PubMed: 10932190). Beyond its structural roles, OPA1 is essential for sequestering cytochrome c within the cristae, thereby regulating the intrinsic apoptotic pathway (NCBI Gene: 4976). Mutations in the OPA1 gene are the leading cause of autosomal dominant optic atrophy (ADOA), a condition characterized by the progressive loss of retinal ganglion cells and optic nerve degeneration (StatPearls: NBK1478). In addition to ADOA, OPA1 dysfunction has been implicated in broader neurodegenerative processes, including Parkinson's and Alzheimer's diseases, due to its impact on mitochondrial DNA stability and oxidative phosphorylation (PubMed: 26073165). While there are currently no FDA-approved drugs that directly target OPA1, therapeutic strategies under investigation include gene therapies and antisense oligonucleotides like PYC-001 aimed at restoring OPA1 expression levels (PYC Therapeutics). Small molecule stabilizers such as MYLS22 are also being explored to enhance mitochondrial network balance in disease states (PubMed: 31919146).

Other names
Dynamin-like 120 kDa protein mitochondrialOptic atrophy 1 (autosomal dominant)KIAA0453MGM1
02

Mechanism of action

Upregulation of OPA1 protein expression or stabilization of mitochondrial inner membrane fusion and cristae structure.

03

Biological functions

Mitochondrial fusionMitochondrial cristae organizationApoptosis regulationMitochondrial DNA maintenance
04

Disease associations

Autosomal dominant optic atrophyBehr syndromeNeurodegenerative diseaseMitochondrial DNA depletion syndrome
05

Safety considerations

Potential for mitochondrial hyperfusionSystemic delivery challengesDisruption of the fission-fusion balance
06

Interacting drugs

PYC-001

3 more in the full profile.

07

Biomarkers

Retinal nerve fiber layer (RNFL) thicknessVisual acuityMitochondrial morphologyOPA1 protein levels

Beyond the preview

Go deeper on Optic atrophy 1 mitochondrial dynamin-like GTPase (OPA1) (OPA1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Optic atrophy 1 mitochondrial dynamin-like GTPase (OPA1) (OPA1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call